Malik Fady Ibraham: insider trades.
Malik Fady Ibraham reported 11 non-derivative transactions on 6 SEC ownership filings in Q3 2026: 0 open-market purchases and 5 sales ($1.4M), across 2 companies.
- Transactions
- 11
- Purchases (P)
- 0
- Sales (S)
- 5
- Companies
- 2
- Name as filed
- Malik Fady Ibraham
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Cytokinetics Inc (CYTK) | Officer · EVP Research & Development | 10 |
| Rocket Pharmaceuticals, Inc. (RCKT) | Director | 1 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-22 | Cytokinetics Inc | M | 3,500 | $7.8 | 157,402 | Form 4 |
| 2026-09-22 | Cytokinetics Inc | S | 3,500 | $68.29 | 153,902 | Form 4 |
| 2026-09-08 | Cytokinetics Inc | M | 3,500 | $7.8 | 157,402 | Form 4 |
| 2026-09-08 | Cytokinetics Inc | S | 3,500 | $75.46 | 153,902 | Form 4 |
| 2026-08-18 | Cytokinetics Inc | M | 3,500 | $7.8 | 157,402 | Form 4 |
| 2026-08-18 | Cytokinetics Inc | S | 3,500 | $75.82 | 153,902 | Form 4 |
| 2026-07-21 | Cytokinetics Inc | M | 3,500 | $7.8 | 157,402 | Form 4 |
| 2026-07-21 | Cytokinetics Inc | S | 3,500 | $80.59 | 153,902 | Form 4 |
| 2026-07-07 | Cytokinetics Inc | S | 3,500 | $86.62 | 153,902 | Form 4 |
| 2026-07-07 | Cytokinetics Inc | M | 3,500 | $7.8 | 157,402 | Form 4 |
| 2026-06-18 | Rocket Pharmaceuticals, Inc. | A | 22,862 | $0 | 52,862 | Form 4 |
Questions
What stock did Malik Fady Ibraham buy or sell?
Malik Fady Ibraham reported 11 non-derivative transactions on 6 SEC ownership filings in Q3 2026: 0 open-market purchases and 5 sales ($1.4M), across 2 companies.
Is Malik Fady Ibraham the same person as other filers with this name?
This page covers SEC CIK 1551778 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/malik-fady-ibraham-1551778.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.